Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label attachment file name title
tabling member	label

Search

100022

	registered interest
	date	15/10/2014
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Patient Choice Schemes
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, what steps he is taking to promote patient choice.
	tabling member constituency	Stroud
	tabling member printed	Neil Carmichael
	uin	905559
	answer	answer is ministerial correction date of answer 21/10/2014 answer text <p>We are committed to patients having greater choice and control over their healthcare, as this can help drive up standards and improve patient care.</p><p> </p><p> </p><p> </p><p>We believe that patient empowerment is vital to the National Health Service in the 21st century. This Government is committed to continuing to develop digital platforms to enable this to happen, such as My NHS and the NHS e-Referral Service.</p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 21/10/2014 16:00:56 answering member 4020 label Biography information for George Freeman
	tabling member	4104 label Biography information for Neil Carmichael

100411

	registered interest
	date	22/10/2014
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Cystic Fibrosis
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, what steps the Government is taking to support research into new treatments for people with cystic fibrosis.
	tabling member constituency	Barnsley Central
	tabling member printed	Dan Jarvis
	uin	211584
	answer	answer is ministerial correction date of answer 27/10/2014 answer text <p>The National Institute for Health Research (NIHR) Evaluation, Trials and Studies Coordinating Centre manages the Efficacy and Mechanism Evaluation programme. With funding from the Medical Research Council, this programme is currently supporting a £3.3 million trial of repeated application of gene therapy in patients with cystic fibrosis. The report of this trial is expected to be published in August 2015.</p><p> </p><p><strong> </strong></p><p> </p><p>A range of commercial and researcher-led cystic fibrosis treatment trials and studies are hosted by NIHR research infrastructure including the NIHR Clinical Research Network, NIHR biomedical research centres and units, and NIHR clinical research facilities for experimental medicine.</p><p> </p><p><strong> </strong></p><p> </p><p><strong> </strong></p><p> </p><p><strong> </strong></p><p> </p><p><strong> </strong></p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 27/10/2014 16:52:12 answering member 4020 label Biography information for George Freeman
	tabling member	4243 label Biography information for Dan Jarvis

79074

	registered interest
	date	21/07/2014
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Congenital Myasthenic Syndrome
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, what discussions he has had with the British Medical Association on the prescribing of salbutamol to treat congenital myasthenia.
	tabling member constituency	Strangford
	tabling member printed	Jim Shannon
	uin	206798
	answer	answer is ministerial correction date of answer 04/09/2014 answer text <p>Ministers have had no such discussions.</p><p>Salbutamol is not licenced for the treatment of congenital myasthenia. Doctors can prescribe a medicine outside the terms of its licence if this best meets the clinical need of an individual patient and on condition that they retain full clinical responsibility for that patient.</p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 04/09/2014 13:56:17 answering member 4020 label Biography information for George Freeman
	tabling member	4131 label Biography information for Jim Shannon

79378

	registered interest
	date	22/07/2014
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Radiotherapy
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, pursuant to the Answer of 21 July 2014, Official Report, column 1007W, on radiotherapy, when data relating to individual funding requests per indication for radiotherapy treatment made to NHS England and the number of such requests refused will be available from NHS England.
	tabling member constituency	Wells
	tabling member printed	Tessa Munt
	uin	206964
	answer	answer is ministerial correction date of answer 04/09/2014 answer text <p> </p><p>NHS England has advised us that it is aiming to complete its work on improving data collection for individual funding requests later this year. This will include information on requests received for radiotherapy treatments.</p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 04/09/2014 13:29:56 answering member 4020 label Biography information for George Freeman
	tabling member	4089 label Biography information for Tessa Munt

89678

	registered interest
	date	29/08/2014
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Crohn's Disease
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, what support his Department is giving to King's College London to work on developing the MAP vaccine for Crohn's disease from animal testing to human trials.
	tabling member constituency	Elmet and Rothwell
	tabling member printed	Alec Shelbrooke
	uin	207417
	answer	answer is ministerial correction date of answer 05/09/2014 answer text <p>The Department's National Institute for Health Research (NIHR) is not currently funding any Crohn’s vaccine development work at King’s College London.</p><p>The Government has funding mechanisms in place for research and development relating to innovative medicines.</p><p>The NIHR welcomes funding applications for research into any aspect of human health, including Crohn’s disease and vaccines. These applications are subject to peer review and judged in open competition, with awards being made on the basis of the importance of the topic to patients and health and care services, value for money and scientific quality.</p><p>The NIHR manages the Efficacy and Mechanism Evaluation programme, which bridges the gap between preclinical studies and evidence of clinical efficacy. The aim is to secure the progress of new technologies and interventions through their early clinical trials and onto larger, later clinical trials. The programme is funded by the Medical Research Council (MRC) and the NIHR.</p><p>Other sources of funding include the Biomedical Catalyst, which is a funding programme jointly operated by the MRC and Innovate UK. The programme provides responsive and effective support for the best translational life science opportunities arising. Grants are available to United Kingdom academics and small and medium enterprises seeking to move their research more quickly from discovery to commercialisation.</p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman grouped question UIN 207271 question first answered 05/09/2014 09:54:16 answering member 4020 label Biography information for George Freeman
	tabling member	3997 label Biography information for Sir Alec Shelbrooke

89685

	registered interest
	date	29/08/2014
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Parkinson's Disease
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, how many of the NHS trusts involved in the Sign up to safety campaign have a policy of stocking medicines for the treatment of Parkinson's disease in their emergency medications cupboards.
	tabling member constituency	Belfast East
	tabling member printed	Naomi Long
	uin	207495
	answer	answer is ministerial correction date of answer 05/09/2014 answer text <p>Following publication of the National Institute for Health and Care Excellence (NICE) guidance that people with Parkinson's disease should have their medication given at appropriate times and should be allowed to self-administer if necessary, the National Patient Safety Agency issued a rapid response report (RRR) on omitted and delayed medicines on 24 February 2010, (NSPA/2010/RRR009) <em>Reducing harm from omitted and delayed medicines in hospital</em>, which applies to the National Health Service in both England and Wales. A copy of this report has already been placed in the Library, and a copy is available at:</p><p>www.nrls.npsa.nhs.uk/resources/patient-safety-topics/medication-safety/?entryid45=66720&amp;p=2</p><p>Under the Health and Social Care Act 2008, all providers of regulated activities, including care homes have to register with the Care Quality Commission, the independent regulator of health and adult social care providers in England, and meet a set of requirements of safety and quality. One of these requirements relates to the management of medicines and requires that a provider protects service users against the risks associated with the unsafe use and management of medicines.</p><p>NHS England’s Safer Medication Practice Team in Patient Safety, is finalising an e-learning package to help reduce omission and delay in the administration of medicines, including for Parkinson’s disease. This package will be available for all health professionals who prescribe, dispense and administer medicines in hospitals. It aims to increase awareness of the frequency of incidents and harm that are associated with omitted and delayed medicine doses in hospital and describes safer practice</p><p>In addition, in March 2014, a joint NHS England and The Medicines and Healthcare products Regulatory Agency Patient Safety Alert, ‘Improving medication error incident reporting and learning’, was issued. A copy of this has been placed in the Library and is available at:</p><p>www.england.nhs.uk/wp-content/uploads/2014/03/psa-med-error.pdf</p><p>This alert directs NHS and independent sector organisations to identify medication safety officers by 19 September 2014. They will be empowered to champion and facilitate local learning from patient safety incidents, including those that arise from omissions and delay of medicines for Parkinson’s disease. A National Medication Safety Network is to be established for discussing potential and recognised safety issues and identifying trends and actions to improve the safe use of medicines. The network will also work with new Patient Safety Improvement Collaborative, that will be set up later this year</p><p>NHS England does not hold information on the number of NHS trusts that are involved with the Sign up to Safety campaign or the number of trusts who have a policy of stocking medicines for the treatment of Parkinson’s disease in their emergency medicines cupboards.</p><p>The NPSA RRR referred to above, identified medicines used to treat Parkinson’s disease as critical medicines. Although emergency medicine cupboards are not mentioned directly in the RRR, NHS organisations have to review and where necessary make changes to systems for the supply of critical medicines within and outside of hours to minimise risks related to omitted or delayed doses of medicines.</p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman grouped question UIN 207493 207494 question first answered 05/09/2014 10:54:06 answering member 4020 label Biography information for George Freeman attachment 1 file name PQ207495 Lib doc Patient Safety Alert.pdf title Improving medication error incident reporting
	tabling member	3920 label Biography information for Naomi Long

89690

	registered interest
	date	29/08/2014
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Parkinson's Disease
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, what steps his Department has taken to improve compliance in (a) hospitals and (b) care homes with the National Institute for Health and Care Excellence guidelines that people with Parkinson's disease should have their medication given at appropriate times and should be allowed to self-administer if necessary.
	tabling member constituency	Belfast East
	tabling member printed	Naomi Long
	uin	207493
	answer	answer is ministerial correction date of answer 05/09/2014 answer text <p>Following publication of the National Institute for Health and Care Excellence (NICE) guidance that people with Parkinson's disease should have their medication given at appropriate times and should be allowed to self-administer if necessary, the National Patient Safety Agency issued a rapid response report (RRR) on omitted and delayed medicines on 24 February 2010, (NSPA/2010/RRR009) <em>Reducing harm from omitted and delayed medicines in hospital</em>, which applies to the National Health Service in both England and Wales. A copy of this report has already been placed in the Library, and a copy is available at:</p><p>www.nrls.npsa.nhs.uk/resources/patient-safety-topics/medication-safety/?entryid45=66720&amp;p=2</p><p>Under the Health and Social Care Act 2008, all providers of regulated activities, including care homes have to register with the Care Quality Commission, the independent regulator of health and adult social care providers in England, and meet a set of requirements of safety and quality. One of these requirements relates to the management of medicines and requires that a provider protects service users against the risks associated with the unsafe use and management of medicines.</p><p>NHS England’s Safer Medication Practice Team in Patient Safety, is finalising an e-learning package to help reduce omission and delay in the administration of medicines, including for Parkinson’s disease. This package will be available for all health professionals who prescribe, dispense and administer medicines in hospitals. It aims to increase awareness of the frequency of incidents and harm that are associated with omitted and delayed medicine doses in hospital and describes safer practice</p><p>In addition, in March 2014, a joint NHS England and The Medicines and Healthcare products Regulatory Agency Patient Safety Alert, ‘Improving medication error incident reporting and learning’, was issued. A copy of this has been placed in the Library and is available at:</p><p>www.england.nhs.uk/wp-content/uploads/2014/03/psa-med-error.pdf</p><p>This alert directs NHS and independent sector organisations to identify medication safety officers by 19 September 2014. They will be empowered to champion and facilitate local learning from patient safety incidents, including those that arise from omissions and delay of medicines for Parkinson’s disease. A National Medication Safety Network is to be established for discussing potential and recognised safety issues and identifying trends and actions to improve the safe use of medicines. The network will also work with new Patient Safety Improvement Collaborative, that will be set up later this year</p><p>NHS England does not hold information on the number of NHS trusts that are involved with the Sign up to Safety campaign or the number of trusts who have a policy of stocking medicines for the treatment of Parkinson’s disease in their emergency medicines cupboards.</p><p>The NPSA RRR referred to above, identified medicines used to treat Parkinson’s disease as critical medicines. Although emergency medicine cupboards are not mentioned directly in the RRR, NHS organisations have to review and where necessary make changes to systems for the supply of critical medicines within and outside of hours to minimise risks related to omitted or delayed doses of medicines.</p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman grouped question UIN 207494 207495 question first answered 05/09/2014 10:54:05 answering member 4020 label Biography information for George Freeman attachment 1 file name PQ207495 Lib doc Patient Safety Alert.pdf title Improving medication error incident reporting
	tabling member	3920 label Biography information for Naomi Long

89693

	registered interest
	date	29/08/2014
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Parkinson's Disease
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, what steps the new NHS safety action team plans to take to reduce avoidable harm resulting from delays or omissions in medication for hospital patients with Parkinson's disease.
	tabling member constituency	Belfast East
	tabling member printed	Naomi Long
	uin	207494
	answer	answer is ministerial correction date of answer 05/09/2014 answer text <p>Following publication of the National Institute for Health and Care Excellence (NICE) guidance that people with Parkinson's disease should have their medication given at appropriate times and should be allowed to self-administer if necessary, the National Patient Safety Agency issued a rapid response report (RRR) on omitted and delayed medicines on 24 February 2010, (NSPA/2010/RRR009) <em>Reducing harm from omitted and delayed medicines in hospital</em>, which applies to the National Health Service in both England and Wales. A copy of this report has already been placed in the Library, and a copy is available at:</p><p>www.nrls.npsa.nhs.uk/resources/patient-safety-topics/medication-safety/?entryid45=66720&amp;p=2</p><p>Under the Health and Social Care Act 2008, all providers of regulated activities, including care homes have to register with the Care Quality Commission, the independent regulator of health and adult social care providers in England, and meet a set of requirements of safety and quality. One of these requirements relates to the management of medicines and requires that a provider protects service users against the risks associated with the unsafe use and management of medicines.</p><p>NHS England’s Safer Medication Practice Team in Patient Safety, is finalising an e-learning package to help reduce omission and delay in the administration of medicines, including for Parkinson’s disease. This package will be available for all health professionals who prescribe, dispense and administer medicines in hospitals. It aims to increase awareness of the frequency of incidents and harm that are associated with omitted and delayed medicine doses in hospital and describes safer practice</p><p>In addition, in March 2014, a joint NHS England and The Medicines and Healthcare products Regulatory Agency Patient Safety Alert, ‘Improving medication error incident reporting and learning’, was issued. A copy of this has been placed in the Library and is available at:</p><p>www.england.nhs.uk/wp-content/uploads/2014/03/psa-med-error.pdf</p><p>This alert directs NHS and independent sector organisations to identify medication safety officers by 19 September 2014. They will be empowered to champion and facilitate local learning from patient safety incidents, including those that arise from omissions and delay of medicines for Parkinson’s disease. A National Medication Safety Network is to be established for discussing potential and recognised safety issues and identifying trends and actions to improve the safe use of medicines. The network will also work with new Patient Safety Improvement Collaborative, that will be set up later this year</p><p>NHS England does not hold information on the number of NHS trusts that are involved with the Sign up to Safety campaign or the number of trusts who have a policy of stocking medicines for the treatment of Parkinson’s disease in their emergency medicines cupboards.</p><p>The NPSA RRR referred to above, identified medicines used to treat Parkinson’s disease as critical medicines. Although emergency medicine cupboards are not mentioned directly in the RRR, NHS organisations have to review and where necessary make changes to systems for the supply of critical medicines within and outside of hours to minimise risks related to omitted or delayed doses of medicines.</p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman grouped question UIN 207493 207495 question first answered 05/09/2014 10:54:06 answering member 4020 label Biography information for George Freeman attachment 1 file name PQ207495 Lib doc Patient Safety Alert.pdf title Improving medication error incident reporting
	tabling member	3920 label Biography information for Naomi Long

89698

	registered interest
	date	29/08/2014
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Neuroblastoma
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, what steps his Department is taking to support research into neuroblastoma.
	tabling member constituency	North Ayrshire and Arran
	tabling member printed	Katy Clark
	uin	207129
	answer	answer is ministerial correction date of answer 04/09/2014 answer text <p> </p><p>The Department’s National Institute for Health Research (NIHR) is supporting neuroblastoma research through NIHR biomedical research centres, the NIHR clinical research facility at the Royal Marsden Hospital, Experimental Cancer Medicine Centres (funded jointly with Cancer Research UK) and the NIHR Clinical Research Network. A study of re-purposing of 13-cis-retinoic acid for use in treating children with neuroblastoma has recently been approved for funding through the Health Innovation Challenge Fund. This is a fund jointly supported by the Department and the Wellcome Trust.</p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 04/09/2014 13:33:31 answering member 4020 label Biography information for George Freeman
	tabling member	1590 label Biography information for Baroness Clark of Kilwinning

89713

	registered interest
	date	29/08/2014
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Crohn's Disease
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, what support his Department is providing to King's College London to assist the development of the MAP vaccine for Crohn's disease from animal testing to human trials.
	tabling member constituency	Elmet and Rothwell
	tabling member printed	Alec Shelbrooke
	uin	207271
	answer	answer is ministerial correction date of answer 05/09/2014 answer text <p>The Department's National Institute for Health Research (NIHR) is not currently funding any Crohn’s vaccine development work at King’s College London.</p><p>The Government has funding mechanisms in place for research and development relating to innovative medicines.</p><p>The NIHR welcomes funding applications for research into any aspect of human health, including Crohn’s disease and vaccines. These applications are subject to peer review and judged in open competition, with awards being made on the basis of the importance of the topic to patients and health and care services, value for money and scientific quality.</p><p>The NIHR manages the Efficacy and Mechanism Evaluation programme, which bridges the gap between preclinical studies and evidence of clinical efficacy. The aim is to secure the progress of new technologies and interventions through their early clinical trials and onto larger, later clinical trials. The programme is funded by the Medical Research Council (MRC) and the NIHR.</p><p>Other sources of funding include the Biomedical Catalyst, which is a funding programme jointly operated by the MRC and Innovate UK. The programme provides responsive and effective support for the best translational life science opportunities arising. Grants are available to United Kingdom academics and small and medium enterprises seeking to move their research more quickly from discovery to commercialisation.</p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman grouped question UIN 207417 question first answered 05/09/2014 09:54:15 answering member 4020 label Biography information for George Freeman
	tabling member	3997 label Biography information for Sir Alec Shelbrooke